טוען...
Targeting cancer with antibody-drug conjugates: Promises and challenges
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis Group
2021-01-01
|
| סדרה: | mAbs |
| נושאים: | |
| גישה מקוונת: | https://www.tandfonline.com/doi/10.1080/19420862.2021.1951427 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|